Cargando…
CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
In the past decade, the emergence of chimeric antigen receptor (CAR) T-cell therapy has led to a cellular immunotherapy revolution against various cancers. Although CAR-T cell therapies have demonstrated remarkable efficacy for patients with certain B cell driven hematological malignancies, further...
Autores principales: | Huang, Jiawen, Huang, Xiaobing, Huang, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557333/ https://www.ncbi.nlm.nih.gov/pubmed/36248810 http://dx.doi.org/10.3389/fimmu.2022.1019115 |
Ejemplares similares
-
Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023) -
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
por: Zhang, Xiaomin, et al.
Publicado: (2022) -
The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021) -
Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
por: Liu, Qianzhen, et al.
Publicado: (2022) -
Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing
por: Zhang, Tingting, et al.
Publicado: (2022)